Dajun Yang

发表

MI-219-Zinc Combination: a new Paradigm in MDM2 Inhibitor Based Therapy

Dajun Yang, Asfar S. Azmi, Fazlul H. Sarkar, 2010, Oncogene.

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Dajun Yang, Su Qiu, Guoping Wang, 2008, Proceedings of the National Academy of Sciences.

Bioinformatics-based discovery and characterization of an AKT-selective inhibitor 9-chloro-2-methylellipticinium acetate (CMEP) in breast cancer cells.

Shaomeng Wang, Xueliang Fang, Dajun Yang, 2007, Cancer letters.

Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins.

H. Abaan, Shaomeng Wang, Renxiao Wang, 2006, Journal of medicinal chemistry.

Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database.

Dajun Yang, Xueliang Fang, Renxiao Wang, 2004 .

A novel Smac mimetic APG-1387 demonstrates potent antitumor activity in nasopharyngeal carcinoma cells by inducing apoptosis.

Yi-Fan Lian, Dajun Yang, Y. Zeng, 2016, Cancer Letters.

(-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer.

Shaomeng Wang, T. Lawrence, Dajun Yang, 2005, Molecular cancer therapeutics.

Structural basis for a non-phosphorus-containing cyclic peptide binding to Grb2-SH2 domain with high affinity.

Dajun Yang, P. Roller, P. Li, 2003, Biochemical and biophysical research communications.

Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists.

Shaomeng Wang, Dajun Yang, M. Lippman, 2003, Seminars in oncology.

Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo

Sanjeev Banerjee, Shaomeng Wang, R. Mohammad, 2008, Cancer biology & therapy.

SUCI02 inhibits the erbB‐2 tyrosine kinase receptor signaling pathway and arrests the cell cycle in G1 phase in breast cancer cells

Dajun Yang, Y. Zeng, Xiao-Feng Zhu, 2006, Cancer science.

Houttuyninum, an active constituent of Chinese herbal medicine, inhibits phosphorylation of HER2/neu receptor tyrosine kinase and the tumor growth of HER2/neu-overexpressing cancer cells.

Dajun Yang, G. Feng, Xiao-Feng Zhu, 2012, Life sciences.

Apogossypolone, a small-molecule inhibitor of Bcl-2, induces radiosensitization of nasopharyngeal carcinoma cells by stimulating autophagy.

Dajun Yang, R. Deng, Xiao-Feng Zhu, 2014, International journal of oncology.

A novel Bcl-2 small molecule inhibitor 4-(3-methoxy-phenylsulfannyl)-7-nitro-benzofurazan-3-oxide (MNB)-induced apoptosis in leukemia cells

Shaomeng Wang, R. Mohammad, Renxiao Wang, 2007, Annals of Hematology.

Induction of sensitivity to doxorubin and etoposide by transfection of MCF-7 breast cancer cells with here β-2

R. Lupu, Dajun Yang, L. Harris, 1998 .

Synthesis of the First α‐Fluoro‐Phosphotyrosyl Mimetic

Dajun Yang, T. Burke, Manchao Zhang, 2004 .

Targeting Antiapoptotic Bcl-2 Family Members with AT-101 in Pre-Clinical Models of Aggressive Lymphoma in Combination with Cyclophosphamide (C) and Rituximab (R) Produces a Marked Improvement in Therapeutic Efficacy.

M. Gonen, Dajun Yang, O. O’Connor, 2005 .

Smac Mimetics in Combination with TRAIL Selectively Target Cancer Stem Cells in Nasopharyngeal Carcinoma

Dajun Yang, Y. Zeng, J. Bei, 2013, Molecular Cancer Therapeutics.

A novel BCL-2 inhibitor APG-2575 exerts synthetic lethality with BTK or MDM2-P53 inhibitor in Diffuse Large B-Cell Lymphoma.

Jian Sun, H. Yi, Dajun Yang, 2020, Oncology research.

Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models

Shaomeng Wang, Dajun Yang, Jianyong Chen, 2022, BMC cancer.

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Dajun Yang, Ya-Zhen Qin, Q. Jiang, 2022, Journal of Hematology & Oncology.

Burden of tyrosine kinase inhibitor failure in Chinese chronic myeloid leukemia patients: a systematic literature review.

Dajun Yang, Y. Zhai, Wendong Chen, 2022, Journal of comparative effectiveness research.

ApoG2 induces cell cycle arrest of nasopharyngeal carcinoma cells by suppressing the c-Myc signaling pathway

Dajun Yang, Y. Zeng, Xiao-Feng Zhu, 2009, Journal of Translational Medicine.

XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells

Dajun Yang, R. Deng, G. Feng, 2018, Theranostics.

A potent bivalent Smac mimetic (SM-1200) achieving rapid, complete, and durable tumor regression in mice.

Liu Liu, Shaomeng Wang, Dajun Yang, 2013, Journal of medicinal chemistry.

Light stimulates IFNgamma-mediated intercellular adhesion molecule-1 upregulation of cancer cells.

Xin-Yuan Fu, Dajun Yang, Y. Zhai, 2003, Human immunology.

A phase I study of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor.

A. Tolcher, K. Papadopoulos, D. Rasco, 2018 .

338 BM-1252 (APG-1252): a potent dual specific Bcl-2/Bcl-xL inhibitor that achieves complete tumor regression with minimal platelet toxicity

Liu Liu, Shaomeng Wang, Chao-yie Yang, 2014 .

A Phase I Study of Novel Bcl‐2/Bcl‐xL Inhibitor APG‐1252 in Patients with Advanced SCLC or Other Solid Tumor: OA12

D. Rasco, Y. Wu, Dajun Yang, 2018, Journal of Thoracic Oncology.

Development of a phosphatase-stable phosphotyrosyl mimetic suitably protected for the synthesis of high-affinity Grb2 SH2 domain-binding ligands.

Dajun Yang, T. Burke, Bihua Li, 2002, Bioorganic & medicinal chemistry letters.

Design and synthesis of a beta-amino phosphotyrosyl mimetic suitably protected for peptide synthesis.

Dajun Yang, T. Burke, Manchao Zhang, 2002, Bioorganic & medicinal chemistry letters.

Synthesis of a phosphotyrosyl analogue having χ1, χ2 and φ angles constrained to values observed for an SH2 domain-bound phosphotyrosyl residue

C. George, Dajun Yang, T. Burke, 2003 .

Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.

Shanghai Yu, Dajun Yang, Su Qiu, 2009, Journal of medicinal chemistry.

Discovery of 4-((3′R,4′S,5′R)-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development

Liu Liu, Shaomeng Wang, Dajun Yang, 2017, Journal of medicinal chemistry.

A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment.

Tao Zhang, Dajun Yang, Su Qiu, 2011, Journal of medicinal chemistry.

LIGHT sensitizes IFNγ–mediated apoptosis of HT-29 human carcinoma cells through both death receptor and mitochondria pathways

Dajun Yang, Y. Zhai, L. Demchik, 2004, Cell Research.

Dajun Yang, Xueliang Fang, Renxiao Wang, 2004, Journal of medicinal chemistry.

Synthesis of N-Fmoc 3-(4-(di-(tert-butyl)phosphonomethyl)-phenyl)pipecolic acid as a conformationally constrained phosphotyrosyl mimetic suitably protected for peptide synthesis

Dajun Yang, T. Burke, X. Wang, 2002 .

Potent, orally bioavailable diazabicyclic small-molecule mimetics of second mitochondria-derived activator of caspases.

Dajun Yang, Su Qiu, Han Yi, 2008, Journal of medicinal chemistry.

ApoG2, a novel inhibitor of antiapoptotic Bcl‐2 family proteins, induces apoptosis and suppresses tumor growth in nasopharyngeal carcinoma xenografts

Dajun Yang, Y. Zeng, Jing Wang, 2008, International journal of cancer.

Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma.

K. Manova, M. Gonen, Dajun Yang, 2008, Blood.

MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment

Dajun Yang, Y. Zhai, P. Zou, 2019, Journal of Immunotherapy for Cancer.

APG-1252-12A induces mitochondria-dependent apoptosis through inhibiting the antiapoptotic proteins Bcl-2/Bcl-xl in HL-60 cells.

H. Yi, Dajun Yang, Jing Wang, 2017, International journal of oncology.

APG-1252-12 A induces mitochondria-dependent apoptosis through inhibiting the antiapoptotic proteins Bcl-2 / Bcl-xl in HL-60 cells

Dajun Yang, Jing Wang, M. Qiu, 2022 .

p27 degradation by an ellipticinium series of compound via ubiquitin-proteasome pathway

Shaomeng Wang, Dajun Yang, Yi Sun, 2007, Cancer biology & therapy.

LIGHT sensitizes IFNgamma-mediated apoptosis of MDA-MB-231 breast cancer cells leading to down-regulation of anti-apoptosis Bcl-2 family members.

Dajun Yang, Y. Zhai, Manchao Zhang, 2003, Cancer letters.

Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells

H. Kantarjian, I. Samudio, G. Borthakur, 2010, Leukemia & lymphoma.

A small molecule compound inhibits AKT pathway in ovarian cancer cell lines.

Shaomeng Wang, Dajun Yang, Jiayuh Lin, 2006, Gynecologic oncology.

Induction of apoptosis and antitumor effects of a small molecule inhibitor of Bcl-2 and Bcl-xl, gossypol acetate, in multiple myeloma in vitro and in vivo.

Dajun Yang, Yongqiang Zhao, J. Lin, 2013, Oncology reports.

An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals

A. Azmi, Shaomeng Wang, R. Mohammad, 2009, Molecular Cancer.

Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy.

Zhiwei Wang, A. Azmi, Sanjeev Banerjee, 2010, Current cancer drug targets.

Pattern of distant metastases in colorectal cancer: a SEER based study

Dajun Yang, R. Xu, M. Qiu, 2015, Oncotarget.

A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.

D. Rasco, Dajun Yang, Y. Zhai, 2019, Journal of Clinical Oncology.

FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia

Dajun Yang, Y. Zhai, Hengrui Zhu, 2021, Translational oncology.

Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors

Dajun Yang, Y. Zhai, M. Qiu, 2019, Cell & Bioscience.

Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression.

Liu Liu, Shaomeng Wang, Dajun Yang, 2020, Journal of medicinal chemistry.

Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells

H. Yi, Dajun Yang, Jing Wang, 2017, OncoTarget.

AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis.

H. Bartelink, Dajun Yang, S. Zerp, 2009, Radiation oncology.

Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model

Dajun Yang, Shaomeng Wang, R. Mohammad, 2008, Molecular Cancer.

Strategies of Discovering Small Molecule Drugs Targeting Growth Factor Heregulin

Dajun Yang, 2002 .

MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function.

Zhiwei Wang, A. Azmi, Sanjeev Banerjee, 2010, European journal of cancer.

Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells.

Dajun Yang, Manchao Zhang, Shaomeng Wang, 2003, Biochemical pharmacology.

HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma.

Michael L. Wang, V. Baladandayuthapani, Dajun Yang, 2011, Blood.

Inhibition of the p53 E3 Ligase HDM-2 Induces Apoptosis and DNA Damage–Independent p53 Phosphorylation in Mantle Cell Lymphoma

K. Young, Dajun Yang, Richard J. Jones, 2008, Clinical Cancer Research.

Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors.

Dajun Yang, R. Xu, M. Qiu, 2015, International journal of clinical and experimental pathology.

Synthesis of α,α-disubstituted 4-phosphonophenylalanine analogues as conformationally-constrained phosphotyrosyl mimetics

J. Deschamps, Dajun Yang, Manchao Zhang, 2004 .

Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy.

A. Lukashin, L. Griffith, S. Violette, 2006, Cancer research.

Concise and enantioselective synthesis of Fmoc-Pmp(But)2-OH and design of potent Pmp-containing Grb2-SH2 domain antagonists.

Dajun Yang, P. Roller, Manchao Zhang, 2003, Organic letters.

Pathologic Diagnosis of Pancreatic Adenocarcinoma in the United States: Its Status and Prognostic Value

Fenghua Wang, Dajun Yang, R. Xu, 2016, Journal of Cancer.

MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models

Dajun Yang, Y. Zhai, Yan Yin, 2021, Cell death discovery.

Blockade of AKT activation in prostate cancer cells with a small molecule inhibitor, 9-chloro-2-methylellipticinium acetate (CMEP).

Shaomeng Wang, Xueliang Fang, Dajun Yang, 2007, Biochemical pharmacology.

Increased WNT 6 expression in tumor cells predicts unfavorable survival in esophageal squamous cell carcinoma patients

Dajun Yang, M. Qiu, Jian Sun, 2015 .

Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Dajun Yang, Q. Jiang, Y. Zhai, 2020 .

Potent Grb2-SH2 domain antagonists not relying on phosphotyrosine mimics.

Dajun Yang, Megan L Peach, Manchao Zhang, 2003, Bioorganic & medicinal chemistry letters.

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Dajun Yang, Q. Jiang, Y. Zhai, 2022, Journal of Hematology & Oncology.

A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China

Dajun Yang, Q. Jiang, Xiao-jun Huang, 2022, Blood.

Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

E. Jabbour, Dajun Yang, Y. Zhai, 2022, Blood.

An Updated Safety and Efficacy Results of Phase 1 Study of HQP1351, a Novel 3rd Generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI Resistant Chronic Myeloid Leukemia

Dajun Yang, Q. Jiang, Xiao-jun Huang, 2019, Blood.

PKCβII phosphorylates ACSL4 to amplify lipid peroxidation to induce ferroptosis

Dajun Yang, R. Deng, G. Feng, 2022, Nature Cell Biology.

Preclinical Studies of Apogossypolone, a Novel Pan Inhibitor of Bcl-2 and Mcl-1, Synergistically Potentiates Cytotoxic Effect of Gemcitabine in Pancreatic Cancer Cells

Zhiwei Wang, Sanjeev Banerjee, F. Sarkar, 2010, Pancreas.

A phase I study of a novel MDM2-P53 antagonist APG-115 in Chinese patients with advanced soft tissue sarcomas.

Dajun Yang, Y. Zhai, Li Zhang, 2019, Journal of Clinical Oncology.

The SMAC Mimetic APG-1387 Sensitizes Immune-Mediated Cell Apoptosis in Hepatocellular Carcinoma

Dajun Yang, Xuan Huang, W. Dong, 2018, Front. Pharmacol..

Abstract 2058: BCL-2 selective inhibitor APG-2575 synergizes with BTK inhibitor in preclinical xenograft models of follicular lymphoma and diffuse large B-cell lymphoma

Dajun Yang, Shoulai Gu, Y. Zhai, 2019, Experimental and Molecular Therapeutics.

Promising antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor- (TKI-) resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST).

Dajun Yang, K. Tao, Y. Zhai, 2022, Journal of Clinical Oncology.

Structure-based design of thioether-bridged cyclic phosphopeptides binding to Grb2-SH2 domain.

Dajun Yang, P. Roller, Manchao Zhang, 2003, Bioorganic & medicinal chemistry letters.

High affinity nonphosphorylated cyclic peptide inhibitors of Grb2-SH2/growth factor receptor interactions

Dajun Yang, P. Roller, T. Burke, 2002 .

Apogossypolone targets mitochondria and light enhances its anticancer activity by stimulating generation of singlet oxygen and reactive oxygen species

Dajun Yang, Y. Zeng, Peng Huang, 2011, Chinese journal of cancer.

Utilization of a beta-aminophosphotyrosyl mimetic in the design and synthesis of macrocyclic Grb2 SH2 domain-binding peptides.

Dajun Yang, T. Burke, Manchao Zhang, 2003, Journal of medicinal chemistry.

Macrocyclization in the design of Grb2 SH2 domain-binding ligands exhibiting high potency in whole-cell systems.

Dajun Yang, Manchao Zhang, Dajun Yang, 2003, Journal of medicinal chemistry.

Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients

Fenghua Wang, Dajun Yang, R. Xu, 2014, BMC Cancer.

Synthesis of a C-terminally biotinylated macrocyclic peptide mimetic exhibiting high Grb2 SH2 domain-binding affinity.

Dajun Yang, Robert J Fisher, Zhen-Dan Shi, 2005, Bioorganic & medicinal chemistry.

Potentiating effect of distant sites in non-phosphorylated cyclic peptide antagonists of the Grb2-SH2 domain.

Dajun Yang, Dajun Yang, P. Roller, 2003, Biochemical and biophysical research communications.

Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors

Dajun Yang, Y. Zhai, M. Qiu, 2019, Cell & Bioscience.

Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients

Fenghua Wang, Dajun Yang, R. Xu, 2014, BMC Cancer.

LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer.

B. Kwon, J. Lu, R. Gentz, 1998, The Journal of clinical investigation.

Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells.

Dajun Yang, M. Lippman, M. Lippman, 1999, Microvascular research.

First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).

M. Konopleva, A. Chanan-Khan, Dajun Yang, 2021 .

A novel macrocyclic tetrapeptide mimetic that exhibits low-picomolar Grb2 SH2 domain-binding affinity.

Dajun Yang, Robert J Fisher, Zhen-Dan Shi, 2003, Biochemical and biophysical research communications.

Local Conformational Constraint in the Design of a Grb2 SH2 Domain Inhibitor

Dajun Yang, T. Burke, Jane Wu, 2001 .

544 Preclinical studies of a dual Bcl-2/Bcl-xL inhibitor APG-1252 with strong anti-tumor efficacy and significantly reduced platelet toxicity

Shaomeng Wang, Dajun Yang, D. McEachern, 2014 .

Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells

Shaomeng Wang, Dajun Yang, Jiayuh Lin, 2004, British Journal of Cancer.

Induction of apoptosis and antitumor effects of a small molecule inhibitor of Bcl-2 and Bcl-xl, gossypol acetate, in multiple myeloma in vitro and in vivo.

Dajun Yang, Yongqiang Zhao, J. Lin, 2013, Oncology reports.

AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis

H. Bartelink, Dajun Yang, S. Zerp, 2009, Radiation oncology.

Wealth of opportunity - the C1 domain as a target for drug development.

Megan L. Peach, Dajun Yang, P. Blumberg, 2008, Current drug targets.

Antitumor Activity of Dual BCL-2/BCL-Xl Inhibitor Pelcitoclax (APG-1252) in Natural Killer/T-Cell Lymphoma (NK/TCL)

Dajun Yang, Y. Zhai, L. Rui, 2021, Blood.

Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Dajun Yang, Y. Zhai, Yongping Song, 2022, Journal of Hematology & Oncology.

Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL)

H. Kantarjian, E. Jabbour, Dajun Yang, 2023, Blood.

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Dajun Yang, Y. Zhai, Q. Niu, 2023, Blood.

A phase 2 study of alrizomadlin (APG-115) in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that has failed immuno-oncologic (IO) drugs.

J. Reeves, A. Tolcher, Dajun Yang, 2023, Journal of Clinical Oncology.

MDM2-p53 Inhibitor Alrizomadlin (APG-115) Enhances Antitumor Activity of Pomalidomide in Multiple Myeloma (MM)

Dajun Yang, Y. Zhai, P. Min, 2022, Blood.

Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS)

T. Kadia, Dajun Yang, Y. Zhai, 2022, Blood.